Reports of Practical Oncology and Radiotherapy最新文献

{"title":"High-grade gliomas: a unique cohort? An overview of a complex and heterogeneous histomolecular classification system.","authors":"Gabriele Gaggero","doi":"10.5603/rpor.101990","DOIUrl":"10.5603/rpor.101990","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"524-526"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy of the pleural cavity in patients with primary and secondary malignancies of the pleura.","authors":"Dimcho Georgiev, Marija Jankova, Bozhidar Krastev, Svetlana Bilyukova","doi":"10.5603/rpor.102614","DOIUrl":"10.5603/rpor.102614","url":null,"abstract":"<p><strong>Background: </strong>Although there have been various attempts to find appropriate treatment from best conservative care to multimodal treatments, curative outcomes remain poor.</p><p><strong>Materials and methods: </strong>30 patients with primary and secondary malignant tumors of the pleura were treated in the Radiotherapy Clinic of USHATO during the period from December 2016 to April 2023. Video-assisted thoracoscopic surgery (VATS) and talc pleurodesis was performed in 18 patients (60%). In all patients, radiotherapy for the pleura was performed on a helical tomotherapy machine. In 21 patients (70%), normal fractionated radiotherapy was performed at daily dose of 1.8-2 Gy to total dose of 40 Gy (5 times a week), and in 6 patients (20%), integrated surdosage to 50 Gy was also performed for visible lesions. Hypofractionated radiotherapy (10 fractions of 3 Gy and 4 fractions of 4 Gy) was performed in 3 (10%) patients.</p><p><strong>Results: </strong>Patients were followed up from 1 month to 57 months (median 14 months) or until death. The observed median survival for all patients was 19.2 months [95% confidence interval (CI): 11.5-26.9] (Fig. 3). The 1-, 2- and 3-year survival rates were 40%, 23% and 7% of patients, respectively. Malignant mesothelioma patients had 1-, 2- and 3-year survival rates of 31%, 10% and 0%, respectively. The 1-, 2-, and 3-year survival rates for patients with secondary malignancies were 54%, 45%, and 18%, respectively.</p><p><strong>Conclusion: </strong>Our results suggest that helical tomotherapy is a feasible therapeutic option for patients with malignant mesothelioma or malignant secondary pleural involvement with a reasonable toxicity profile relative to other unaffected lung.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"509-515"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and prognostic factors of volumetric modulated arc therapy (VMAT) of esophageal cancer.","authors":"Tsuyoshi Fukuzawa, Ryuta Nagao, Toshihisa Kuroki, Tatsuya Mikami, Takeshi Akiba, Yoji Nakano, Yuri Toyoda, Tsuyoshi Takazawa, Yoshitsugu Matsumoto, Shigeto Kabuki, Akitomo Sugawara","doi":"10.5603/rpor.101529","DOIUrl":"10.5603/rpor.101529","url":null,"abstract":"<p><strong>Background: </strong>The objective was to evaluate the efficacy and safety of radiotherapy and the prognostic factors in patients with esophageal cancer who received definitive radiotherapy, using volumetric modulated arc therapy (VMAT).</p><p><strong>Materials and methods: </strong>Forty-seven patients who received definitive radiotherapy using VMAT between September 2017 and December 2020 were enrolled. Prescription doses were 60 Gy in 30 fractions to the planning target volume (PTV) primary and 48 Gy in 30 fractions to the PTV subclinical. Overall survival (OS), progression free survival (PFS), and toxicity were analyzed, and univariate and multivariate analyses were used to investigate the prognostic factors.</p><p><strong>Results: </strong>Median follow up time was 10 months. Most of the patients had an advanced disease stage (stage I, 12.8%; II, 8.5%; III, 27.7%; IV, 51.0%) patients (38.3%) had a T4 tumor. The median survival time was 14 months (range: 0-56 months). The 2-year OS and PFS were 31.3% and 20.4%, respectively. Acute adverse events (≥ Grade 3) were observed in 25 patients (53.2%), and the most frequent types were dysphagia, hematological toxicities including leukopenia, and febrile neutropenia in 14 (29.8%), 10 (21%), and 10 (21%) patients, respectively. Late adverse events (Grade 3 or higher) were observed in eight patients (17.0%), and the most frequent types were pneumonitis in four patients (8.5%), and Grade 5 in one patient (2.1%; esophageal fistula). In multivariate analysis, neutrophil-to-lymphocyte ratio (NLR) > 3 (p = 0.026) was significantly associated with poor survival.</p><p><strong>Conclusion: </strong>Definitive radiotherapy of 60Gy with VMAT is feasible and safe for patients with esophageal cancer. Pre-treatment NLR >3 was an independent prognostic factor for OS.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"426-436"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for osteoblastoma: the 25-year institutional experience.","authors":"Bartłomiej Szostakowski, Tadeusz Morysiński, Piotr Rutkowski, Mateusz Jacek Spałek","doi":"10.5603/rpor.101993","DOIUrl":"10.5603/rpor.101993","url":null,"abstract":"<p><strong>Background: </strong>Osteoblastoma (OB) is a rare benign bone tumor, mainly affecting adolescents and young adults. It's commonly found in the spine and long bones, with a male-to-female ratio of 2:1. Surgery, primarily en bloc resection or curettage, is the main treatment. Radiotherapy (RT) or systemic treatment is considered in specific cases. However, optimal RT strategies remain unclear due to limited and outdated data. This study aims to evaluate RT role, efficacy, and safety in treating OB.</p><p><strong>Matrials and methods: </strong>The study group was a cohort of consecutive patients with OB treated in our institute that received RT in years 1998-2023. We analyzed indication for RT, irradiated site, RT technique, total dose, dose per fraction, early and late tolerance, and survival.</p><p><strong>Results: </strong>Thirteen patients meeting the criteria were analyzed. Most were males (10 out of 13) with a median age of 21. Most OBs were within the vertebral column. All patients received definitive RT for unresectable disease and underwent conventionally fractionated RT (1.8-2.0 Gy per fraction) to total doses 40-70.2 Gy. Only mild acute toxicity was observed. No late toxicity was reported. The median follow-up was 118 months. Local progression was observed in four patients, all of whom died.</p><p><strong>Conclusions: </strong>RT is a valuable option for certain OB patients ineligible for surgery. Seeking treatment at specialized bone tumor centers with RT techniques is crucial due to OB's rarity and the lack of standardized guidelines. Recommended RT doses fall between 50-70 Gy using intensity-modulated techniques in conventional 1.8-2 Gy fractions.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"437-444"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary plasmacytoma: should new approaches in diagnosis and treatment be adopted?","authors":"Victoria Represa, Carmen González San-Segundo, Valeria Delgado Pinos, Lucia Biscari García, Patricia Martín Nieto, Franco Fornazari, Cristina Encinas Rodríguez","doi":"10.5603/rpor.101530","DOIUrl":"10.5603/rpor.101530","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) is the gold standard for solitary plasmacytomas (SP) with great local control. The influence of radiotherapy as well as factors on multiple myeloma (MM) progression is unknown.</p><p><strong>Materials and methods: </strong>We present a retrospective study of 27 patients with SP (bone-SBP- and extramedullary-SEP-), treated since 1995 to 2021. We aim to analyze prognostic factors affecting local control and progression to MM in patients treated with radiotherapy (RT).</p><p><strong>Results: </strong>Mean age was 57.3 years. 22 were SBP and 5 SEP. 13 patients were treated with definitive RT, and 14 with a combination of RT and systemic treatment and/or surgery. Local control was observed in 91.5% of cases. 28% experienced progression to MM. With a median follow up of 61.4 months [39.5, 121.6], 5-years MM-free-survival was 81 ± 8%; no individuals progressed further 50 months since diagnosis. Large tumor bulk (> 5 cm) and type (SBP 36% <i>vs</i>. SEP 0%) were associated with progression. Progression was not affected by doses greater than 46 Gy and/or surgery. An immunophenotype different from IgG kappa was predictive of less progression (p = 0.031) in Cox regression analysis adjusted for age, RT dose and tumor bulk > 5 cm. Patients with positron emission tomography-computed tomography (PET-CT) staging showed less MM progression, without statistical differences.</p><p><strong>Conclusion: </strong>RT achieves more than 90% of local control. The immunophenotype IgG kappa showed more risk of progression to MM. Initial staging with PET-CT seems to lead to a better identification of SP. The inclusion of bad prognosis patients in clinical trials would determine the role of adjuvant chemoimmunotherapy in SP treatment.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"501-508"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of patient and tumor characteristics on respiratory motion in early-stage peripheral lung cancer (Tis ~ T2bN0M0) treated with stereotactic body radiation therapy (SBRT).","authors":"Norio Mitsuhashi, Daichi Tominaga, Hajime Ikeda, Fumiya Shiina, Keiko Fukaya, Yoshitaka Nemoto","doi":"10.5603/rpor.101531","DOIUrl":"10.5603/rpor.101531","url":null,"abstract":"<p><strong>Background: </strong>Recent advances in stereotactic body radiation therapy (SBRT) technology for early-stage peripheral lung cancer have been remarkable and are becoming a viable alternative to surgery. However, the most important problem in performing SBRT correctly is minimizing the respiratory motion of the tumor.</p><p><strong>Materials and methods: </strong>Thirty-eight patients treated with SBRT were evaluated to clarify factors affecting respiratory motion of early-stage peripheral lung cancer in the management of restrictive breathing technique (abdominal compression) to reduce respiratory tumor motion in SBRT. We investigated age, gender, body mass index (BMI), Brinkman index (BI), forced expiratory volume in 1 second (FEV 1.0), and type of ventilatory impairment as patient factors, and T-factor, stage, tumor-bearing lung lobe, and tumor pathology as tumor factors. Respiratory motion was assessed by volume differences between clinical target volume (CTV) and internal target volume (ITV). The degree of tumor motion due to respiration was compared using the formula of (ITV-CTV)/CTV as an index.</p><p><strong>Results: </strong>In the results, univariate analyses showed that only age was a significant predictor of respiratory tumor motion (p = 0.048). In multi-variate analyses, only T factor was an independent significant predictor of respiratory tumor motion (p = 0.045), while there was a significant trend for age (p = 0.061), and tumor location (p = 0.067).</p><p><strong>Conclusions: </strong>In late elderly patients or T1a tumor, respiratory motion in early-stage peripheral lung cancer was significantly large. However, it is not predictable by patient and tumor characteristics. Therefore, respiratory motion of the tumor should be measured in all patients in some way.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"468-477"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetry characteristics of polycarbonate/bismuth oxide nanocomposite for real-time application in the field of gamma-rays.","authors":"Amir Veiskarami, Shahryar Malekie, Sedigheh Kashian, Suffian Mohamad Tajudin","doi":"10.5603/rpor.101397","DOIUrl":"10.5603/rpor.101397","url":null,"abstract":"<p><strong>Background: </strong>Polymer-carbon nanostructures have previously been introduced for dosimetry of gamma rays with potential application in radiotherapy. In this research work, bismuth oxide (Bi₂O₃) nanoparticles were added into the amorphous polycarbonate (PC) matrix to enhance the probability of the photoelectric effect and dosimetry response in parallel.</p><p><strong>Materials and methods: </strong>PC/Bi₂O₃ nanocomposites at concentrations of 0, 5, 20, 40, and 50 Bi₂O₃ wt% were fabricated via a solution method. Afterward, the samples were irradiated by gamma rays of cobalt-60 (⁶⁰Co) related to Picker V-9, and Therarton-780 machines at 30-254 mGy/min. Dosimetric characteristics were carried out including linearity, angular dependency, energy, bias-polarity, field size, and repeatability.</p><p><strong>Results: </strong>Field emission scanning electron microscopy (FESEM) and transmission electron microscopy (TEM) analyses exhibited an appropriate dispersion state. The dosimeter response was linear at 30-254 mGy/min for the all samples. The 50 wt% sample exhibited the highest sensitivity at 4.61 nC/mGy. A maximum angular variation of approximately 15% was recorded in normal beam incidence. The energy dependence at two energies of 662 and 1250 keV was obtained as 0.7%. Bias-polarity for the 40, and 50 wt% samples at 400 V were measured as 15.9% and 9.0%, respectively. The dosimetry response was significantly dependent on the radiation field size. Also, the repeatability of the dosimeter response was measured as 0.4%.</p><p><strong>Conclusions: </strong>Considering the dosimetry characteristics of PC-Bi₂O₃ nanocomposites, and appropriate correction factors, this material can be used as a real-time dosimeter for the photon fields at therapy level.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"413-425"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: <i>High platelet count as a predicting factor of histopathological grading among invasive breast cancer individuals: a single centre experience from Indonesia</i>.","authors":"Yi Zheng, Liqi Li","doi":"10.5603/rpor.101099","DOIUrl":"10.5603/rpor.101099","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"523"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of elective nodal irradiation ≥ 60 Gy on severe weight loss during intensity-modulated radiation therapy in patients with head and neck squamous cell carcinoma.","authors":"Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Kei Nagasaki, Noriko Takata, Shintaro Tsuruoka, Kotaro Uwatsu, Sohei Mitani, Naohito Hato, Teruhito Kido","doi":"10.5603/rpor.101532","DOIUrl":"10.5603/rpor.101532","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the association between radiotherapy-related factors and the incidence of severe weight loss (WL) during radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC) in the intensity-modulated radiation therapy (IMRT) era.</p><p><strong>Materials and methods: </strong>Seventy-nine patients with HNSCC who received IMRT between January 2011 and December 2020 were reviewed. The 10% WL was defined as severe WL. The median prescribed doses of IMRT were 70 Gy for the high-risk planning target volume (HRPTV); 60 Gy for the intermediate-risk planning target volume (IRPTV); 54 Gy for the low-risk PTV.</p><p><strong>Results: </strong>Larger volumes of ≥ 60 Gy (PTV60Gy) had a significant impact on WL, whereas volumes of ≥ 70 Gy and ≥ 54 Gy did not. PTV60Gy to the ipsilateral level II or III necks had a significant impact on WL, whereas PTV60Gy to the ipsilateral levels I, IV, V, or VII did not. The primary site of the nasopharynx/oropharynx had a significant impact on WL, whereas the hypopharynx/larynx did not. In the stepwise regression and multivariate analyses, primary site and PTV60Gy volume were important factors for severe WL.</p><p><strong>Conclusions: </strong>Reducing the PTV60Gy volume can be useful in reducing severe WL. Because the clinical significance of IRPTV is unclear, the omission of IRPTV should be considered while balancing risks and benefits.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"460-467"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evaluation of the inflammatory status and systemic antioxidant-oxidant balance of women with breast cancer during adjuvant chemotherapy.","authors":"Joanna Grupińska, Magdalena Budzyń, Jakub Janowski, Bogna Gryszczyńska, Elżbieta Kaja, Jacek J Brzeziński, Ewa Leporowska, Dorota Formanowicz, Witold Kycler","doi":"10.5603/rpor.102130","DOIUrl":"10.5603/rpor.102130","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy may cause systemic inflammation. Therefore, reliable markers monitoring inflammation during cancer treatment are intensively investigated. In our study, we analyzed the concentration of high-sensitivity C-reactive protein (hs-CRP) and selected oxidative stress markers, such as malondialdehyde (MDA), glutathione peroxidase activity (GPx), and total antioxidant capacity (TAC), in breast cancer women before and during adjuvant chemotherapy.</p><p><strong>Materials and methods: </strong>The study included 90 women with breast cancer stratified according to clinicopathological and anthropometric features. Blood samples were taken before and after two cycles of adjuvant chemotherapy.</p><p><strong>Results: </strong>During adjuvant chemotherapy, a significant increase in hs-CRP concentration was noticed in the entire group of patients with breast cancer. After division into appropriate groups, a twofold increase in hs-CRP concentration was particularly observed in patients not expressing steroid hormone receptors and those without metastases in regional lymph nodes. A significant rise in hs-CRP was observed in patients with smaller tumor sizes (2 cm ≤) and with a lower stage of disease [I-IIA according to the tumor-node-metastasis (TNM) classification]. Adjuvant chemotherapy resulted in a significant decrease in GPx activity, especially in patients diagnosed with larger (> 2 cm) and more advanced tumors (IIB-IIIC according to the TNM classification), without metastasis in regional lymph nodes, and without HER-2 expression. A significant decrease in glutathione peroxidase (GPx) activity during adjuvant chemotherapy was also observed in patients with abnormal body mass index (BMI) and body fat content. TAC and MDA values remained unchanged in the entire group of patients and individual subgroups during adjuvant chemotherapy.</p><p><strong>Conclusion: </strong>Our study showed that adjuvant chemotherapy causes systemic inflammation, manifested by increased hs-CRP and altered markers of oxidative stress in the blood of breast cancer patients. The severity of inflammatory processes during adjuvant chemotherapy may depend on specific characteristics of breast cancer and body composition.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 4","pages":"488-500"},"PeriodicalIF":1.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}